The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients
Abstract
Immunotherapy greatly improves clinical outcomes in treated patients with cancer. However, the long-lasting immune response and long duration of therapy could induce long-term adverse effects owing to the chronic inflammation induced. Type 2 diabetes is now recognized as an inflammatory disease. In addition, immunotherapy is concerned with increase in the production of tumor necrosis factor-&agr;, interleukin-2, and interferon-&ggr;, which are involved in the inflammatory process. Based on these observations, we hypothesized that anti-programmed cell death-1 (anti-PD-1) and/or anticytotoxic T-lymphocyte-associated protein-4 therapy could contribute to type 2 diabetes genesis in treated patients. Therefore, to evaluate this hypothesis, we studied HbA1c levels during follow-up in patients treated with anti-PD-1 and/or anticytotoxic T-lymphocyte-associated protein-4 therapy. A prospective and observational study was performed in an oncodermatology department (Saint-Louis Hospital, Paris, France) from March 2015 to February 2017. Sixty-two patients meeting the inclusion criteria were enrolled. Forty-three patients had paired HbA1c measurements during their follow-up period and were analyzed. The median follow-up was 3 months. We noted an increase in HbA1c levels from 5.3% [interquartile range (IQR): 5.1–5.5; range: 4.5–6.2) to 5.45% (IQR: 5.2–5.7; range: 4.7–6.2; P=0.037). This observation was confirmed in the subgroup of patients who did not receive concomitant glucocorticoids;…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of the various immunosuppressive agents, belatacept1582,1583 appears to be the least diabetogenic and tacrolimus having the highest risk for PTDM.1584–1590”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1587]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,358
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
Defining the Relationship Between Plasma Glucose and HbA1c
Rohlfing, C. L., Wiedmeyer, H.-M., Little, R. R., England, J. D., Tennill, A., & Goldstein, D. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.275 · Cited by 987
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 97
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
Marchand, L., Disse, E., Dalle, S., Reffet, S., Vouillarmet, J., Fabien, N., Thivolet, C. H., & Cugnet‐Anceau, C. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01402-w · Cited by 49
Leiter, A., Carroll, E., Brooks, D., Shimol, J. B., Eisenberg, E., Wisnivesky, J. P., Galsky, M. D., & Gallagher, E. J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108633 · Cited by 26
“20% increase in hemoglobin A1C (HbA1c) in patients with metastatic melanoma who received ICI therapy for an average of 3 months [8].”
BackgroundOhara, N., Kobayashi, M., Ikeda, Y., Hoshi, T., Morita, S., Kanefuji, T., Yagi, K., Suda, T., Takada, T., Hasegawa, G., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3208-19 · Cited by 18
“Aspartate aminotransferase 22 IU/L (13-30)”
Background
Metadata
- Authors
- Gauci, M.-L., Boudou, P., Squara, P.-A., Delyon, J., Allayous, C., Mourah, S., Resche-Rigon, M., Lebbé, C., Baroudjian, B., & Gautier, J.-F.
- Affiliations
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- AP-HP Department of Statistics
- AP-HP Department of Dermatology, INSERM U976
- Corresponding author
- Gauci, Marie-Léa
- ORCID
- Venue
- Melanoma Research
- Published
- 2019-06
- Volume
- 29
- Issue
- 3
- Pages
- 328-332
- ISSN
- 0960-8931 (ISSN-L)
- OpenAlex
- W2919158317
- Cited by
- 10
- References
- 19
- Citations by year
- 2026: 2 · 2025: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Melanoma Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 blockade, HbA1c, type 2 diabetes, glucose metabolism, cancer immunotherapy, glucocorticoids, melanoma, chronic inflammation, adverse effects of immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Prognosis, Prospective Studies, Skin Neoplasms, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. https://app.cochat.ai/papers/10.1097/cmr.0000000000000585
- The paper
- Gauci, M.-L., Boudou, P., Squara, P.-A., Delyon, J., Allayous, C., Mourah, S., Resche-Rigon, M., Lebbé, C., Baroudjian, B., & Gautier, J.-F. (2019). Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Research. https://doi.org/10.1097/cmr.0000000000000585
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.